Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Journal: Journal of hepatology
Published: July 07, 2021
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Journal: Journal of hepatology
Published: November 19, 2019
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Journal: Hepatology (Baltimore, Md.)
Published: September 09, 2019
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 31, 2018
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Journal: Gastroenterology
Published: May 23, 2016
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
Journal: Hepatology (Baltimore, Md.)
Published: June 25, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Journal: The New England journal of medicine
Published: April 15, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Journal: The New England journal of medicine
Published: April 12, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
Journal: Hepatology (Baltimore, Md.)
Published: December 12, 2013
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Journal: Hepatology (Baltimore, Md.)
Published: September 28, 2012
Last Updated: 09/26/2026